Vieta E
Institute of Neuroscience, University of Barcelona, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Spain.
ArticleKetamine
Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report.
Article5-MeO-DMT
GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
ArticlePsilocybin
Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.
ArticleMDMA
Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes.
ArticlePsychedelics
Current perspectives on psychedelic treatments in Europe.
ArticleMDMA
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.
ArticleKetamine
Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.
ArticleKetamine
Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.
ArticleKetamine
Improvements in Functioning with Esketamine Nasal Spray versus Quetiapine Extended Release in Patients with Treatment Resistant Depression
ArticleKetamine
Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects.
ArticleKetamine
Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.
ArticleKetamine
Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.
ArticleKetamine